Abstract
The interest in personalized medicine has increased considerably over the last 10 years with an almost exponential growth in the number of publications since 1999 when the first article discussing the subject appeared. However, the foundation of what we perceive today as personalized medicine had already been created in the 1960s with the discovery of the estrogen receptor, and later on, with the development of the selective estrogen receptor modulator drug – tamoxifen. The key driver in today’s personalized medicine is molecular diagnostics, but the need to improve the current pharmacotherapy also plays a very important role. Many of the frequently used drugs are not as effective and safe as they should be. The efficacy rate of drugs within major disease areas such as asthma, cancer, psychiatric illnesses and cardiovascular diseases are in the range of 25–60%. Drug safety is another critical issue which imposes burdens on both patients and society. In the European Union, it is estimated that 5% of all hospital admissions are due to side effects related to pharmacotherapy, thus resulting in nearly 200,000 deaths per year. The total cost related to side effects from therapeutic drugs in the European Union is €79 billion per year. This situation needs to be improved, and this can be achieved by taking differences in the individual patient’s biologies into consideration when the drugs are dispensed. A more individualized pharmacotherapy by the implementation of pharmacodiagnostic testing will be an important aid in improving efficacy and reducing the frequency of serious side effects in the future. However, there are obstacles to be overcome with regard to the implementation of personalized medicine, and besides scientific and economic issues, it will be a challenge to address other aspects, such as regulatory requirements, reimbursement, education and logistics.
Papers of special note have been highlighted as: ▪ of interest ▪▪ of considerable interest
Bibliography
- 1 Langreth R, Waldholz M: New era of personalized medicine – targeting drugs for each unique genetic profile. Oncologist4,426–427 (1999).▪▪ First article to describe the term ‘personalized medicine’.
- 2 Hu SX, Foster T, Kieffaber A: Pharmacogenomics and personalized medicine: mapping of future value creation. BioTechniques39,1–6 (2005).
- 3 Trusheim MR, Berndt ER, Douglas FL: Stratified medicine: strategic and economic implications of combining drugs and clinical biomarkers. Nat. Rev. Drug Discov.6,287–293 (2007).
- 4 Jørgensen JT: Are we approaching the post-blockbuster era? – pharmacodiagnostics and rational drug development. Expert Rev. Mol. Diagn.8,689–695 (2008).
- 5 Jensen EV, Desombre ER, Hurst DJ et al.: Estrogen-receptor interaction in target tissue. Arch. Anat. Microsc. Morphol. Exp.56,547–569 (1967).
- 6 Lerner HJ, Band PR, Israel L, Leung BS: Phase II study of tamoxifen: report of 74 patients with stage IV breast cancer. Cancer Treat. Rep.60,1431–1435 (1976).
- 7 Slamon DJ, Leyland-Jones B, Shak S et al.: Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N. Engl. J. Med.344,783–792 (2001).
- 8 Dahabreh IJ, Linardou H, Siannis F et al.: Trastuzumab in the adjuvant treatment of early-stage breast cancer: a systematic review and meta-analysis of randomized controlled trials. Oncologist13,620–630 (2008).
- 9 Van Cutsem E, Kang H, Chung H et al.: Efficacy results from the ToGA trial: a Phase III study of trastuzumab added to standard chemotherapy in first-line human epidermal growth factor receptor 2 (HER2)-positive advanced gastric cancer. J. Clin. Oncol.27(18S) (2009) (Abstract LBA4509).
- 10 Flockhart DA, Skaar T, Berlin DS et al.: Clinically available pharmacogenomics tests. Clin. Pharmacol. Ther. (2009) (Epub ahead of print).
- 11 Spear BB, Heath-Chiozzi M, Huff J: Clinical application of pharmacogenetics. Trends Mol. Med.7,201–204 (2001).
- 12 Sikora K: Personalized cancer therapy – key to the future. Pharmacogenomics5,225–228 (2004).
- 13 Jørgensen JT: From blockbuster medicine to personalized medicine. Per. Med.5,55–63 (2008).
- 14 Jørgensen JT, Nielsen KV, Ejlertsen B: Pharmacodiagnostics and targeted therapies – a rational approach for individualizing medical anti-cancer therapy in breast cancer. Oncologist12,397–405 (2007).
- 15 Davis JC, Furstenthal L, Desai AA et al.: The microeconomics of personalized medicine: today’s challenge and tomorrow’s promise. Nat. Rev. Drug Discov.8,279–286 (2009).▪ Perspective on the challenges related to the implementation of personalized medicine.
- 101 Medscape. ASCO 2009: Herceptin in gastric cancer — practice changing data www.medscape.com/viewarticle/703845
- 102 US FDA. Prescribing information for maraviroc (Selzentry, Pfizer) www.accessdata.fda.gov/drugsatfda_docs/label/2007/022128lbl.pdf
- 103 Medical News Today. Four studies affirm significance of monogram’s trofile™ HIV co-receptor tropism assay www.medicalnewstoday.com/articles/63005.php
- 104 US FDA. Table of valid genomic biomarkers in the context of approved drug labels Updated 10 September (2008) www.fda.gov/cder/genomics/genomic_biomarkers_table.htm▪ List of biomarkers and their regulatory status in relation to drug labeling in the USA.
- 105 Commission Staff Working Document: SEC(2008) 2671. Commission of the European communities, Brussels, 10 December (2008) http://ec.europa.eu/enterprise/pharmaceuticals/pharmacos/pharmpack_12_2008/pharmacovigilance-summary-ia.pdf
- 106 US FDA: Pharmacogenomics and its role in drug safety – volume 1, number 2 (2008) www.fda.gov/Drugs/DrugSafety/DrugSafetyNewsletter/ucm119991.htm
- 107 US FDA. FDA clears genetic lab test for warfarin sensitivity. September 17 (2007) www.fda.gov/bbs/topics/NEWS/2007/NEW01701.html
- 108 President’s Council of Advisors on Science and Technology. Priorities for personalized medicine (2008) www.ostp.gov/galleries/PCAST/pcast_report_v2.pdf
